# 2025å¹´å…¬å…±å«ç”Ÿæµè¡Œç—…å­¦ç ”ç©¶è¿‘å†µ - å­¦ä¹ ç¬”è®°

## ğŸ“‹ å‰§é›†æ¦‚è§ˆ

| å­—æ®µ | ä¿¡æ¯ |
|------|------|
| **æ’­å®¢æ ‡é¢˜** | 2025å¹´å…¬å…±å«ç”Ÿæµè¡Œç—…å­¦ç ”ç©¶è¿‘å†µ |
| **å‰§é›†ç¼–å·** | 001 |
| **æ—¶é•¿** | 15åˆ†é’Ÿ |
| **éš¾åº¦** | ä¸­çº§ (Intermediate) |
| **ä¸»é¢˜** | æµè¡Œç—…å­¦é‡ç‚¹ç§‘å­¦å‘ç° |
| **ä¸»æ’­** | Matthew |
| **æ—¥æœŸ** | 2026-02-11 |
| **æ¥æº** | Scientific American, Knowable Magazine, JHU |

---

## ğŸ¯ å­¦ä¹ ç›®æ ‡

å®Œæˆæœ¬å‰§é›†å­¦ä¹ åï¼Œä½ å°†èƒ½å¤Ÿï¼š

- [ ] ç†è§£2025å¹´äº”å¤§å…¬å…±å«ç”Ÿå‘ç°
- [ ] æŒæ¡15ä¸ªæ ¸å¿ƒæµè¡Œç—…å­¦æœ¯è¯­
- [ ] ç”¨è‹±è¯­è§£é‡Šç–«è‹—ä¸ç¥ç»é€€è¡Œæ€§ç–¾ç—…çš„å…³ç³»
- [ ] è®¨è®ºGLP-1è¯ç‰©çš„ä½œç”¨æœºåˆ¶
- [ ] æè¿°One Healthç†å¿µ

---

## ğŸ“ å‰§é›†æ‘˜è¦

### ç®€è¦æ¦‚è¿° (3-5å¥è¯)

2025å¹´ï¼Œå°½ç®¡ç§‘å­¦ç ”ç©¶é¢ä¸´èµ„é‡‘å‰Šå‡ç­‰æŒ‘æˆ˜ï¼Œæµè¡Œç—…å­¦é¢†åŸŸä»å–å¾—äº†é‡å¤§çªç ´ã€‚ç ”ç©¶å‘ç°äº†å¸¦çŠ¶ç–±ç–¹ç–«è‹—å¯èƒ½é™ä½é˜¿å°”èŒ¨æµ·é»˜ç—…é£é™©ï¼Œè¯ºè´å°”å¥–è¡¨å½°äº†å…ç–«è°ƒèŠ‚ç»†èƒçš„å‘ç°ï¼ŒGLP-1è¯ç‰©æ­ç¤ºäº†æ”¹å˜é£Ÿç‰©åå¥½çš„æœºåˆ¶ï¼Œç¦½æµæ„Ÿç ”ç©¶å¼ºè°ƒäº†äººç•œå…±æ‚£ç—…é˜²æ§çš„é‡è¦æ€§ã€‚

### æ ¸å¿ƒè¦ç‚¹

1. **å¸¦çŠ¶ç–±ç–¹ç–«è‹—ç ”ç©¶**ï¼šå¨å°”æ–¯ç ”ç©¶æ˜¾ç¤ºç–«è‹—æ¥ç§è€…æ‚£ç—´å‘†ç—‡é£é™©é™ä½20%
2. **è¯ºè´å°”ç”Ÿç†å­¦æˆ–åŒ»å­¦å¥–**ï¼šè¡¨å½°è°ƒèŠ‚æ€§Tç»†èƒåœ¨å…ç–«è€å—ä¸­çš„å…³é”®ä½œç”¨
3. **GLP-1è¯ç‰©æ–°å‘ç°**ï¼šè§£é‡Šé£Ÿç‰©åå¥½å˜åŒ–å’Œé…’ç²¾æ‘„å…¥å‡å°‘çš„æœºåˆ¶
4. **ç¦½æµæ„Ÿè·¨ç‰©ç§ä¼ æ’­**ï¼šH5N1ç—…æ¯’åœ¨å®¶ç¦½ã€ç‰›ç¾¤å’Œé‡ç”ŸåŠ¨ç‰©ä¸­çš„ä¼ æ’­è·¯å¾„
5. **ç”·æ€§é¿å­•è¯çªç ´**ï¼šé¦–ä¸ªé€šè¿‡IæœŸå®‰å…¨è¯•éªŒçš„éæ¿€ç´ å£æœé¿å­•è¯

---

## ğŸ“– è¯æ±‡ç§¯ç´¯

### æ ¸å¿ƒè¯æ±‡ (15ä¸ª)

| ç¼–å· | è¯æ±‡ | éŸ³æ ‡ | è¯æ€§ | å®šä¹‰ | ä¸­æ–‡ | ä¾‹å¥ | é¢‘ç‡ |
|------|------|------|------|------|------|------|------|
| 1 | **Neurodegenerative** | /ËŒnjÊŠÉ™rÉ™ÊŠdÉªËˆdÊ’enÉ™rÉ™tÉªv/ | adj. | ç¥ç»é€€è¡Œæ€§çš„ | ç¥ç»ç»†èƒé€æ¸é€€åŒ–çš„ | "Alzheimer's is the most common neurodegenerative disease." | â˜…â˜…â˜…â˜…â˜† |
| 2 | **Immune tolerance** | /ÉªËˆmjuËn ËˆtÉ’lÉ™rÉ™ns/ | n. | å…ç–«è€å— | å…ç–«ç³»ç»Ÿä¸æ”»å‡»è‡ªèº«ç»„ç»‡ | "Regulatory T cells maintain immune tolerance." | â˜…â˜…â˜…â˜…â˜… |
| 3 | **Hypothesis** | /haÉªËˆpÉ’Î¸É™sÉªs/ | n. | å‡è®¾ | æœªç»è¯å®çš„è§£é‡Šæ€§é™ˆè¿° | "The virus-dementia hypothesis was supported by new evidence." | â˜…â˜…â˜…â˜…â˜† |
| 4 | **Pandemic** | /pÃ¦nËˆdemÉªk/ | n./adj. | å¤§æµè¡Œç—…çš„ | å…¨çƒæ€§ç–¾ç—…æš´å‘ | "Pandemic preparedness requires international cooperation." | â˜…â˜…â˜…â˜…â˜… |
| 5 | **Microbiome** | /ËˆmaÉªkrÉ™ÊŠbaÉªÉ™m/ | n. | å¾®ç”Ÿç‰©ç»„ | ä½“å†…å¾®ç”Ÿç‰©ç¾¤è½ | "The gut microbiome affects overall health." | â˜…â˜…â˜…â˜…â˜… |
| 6 | **Dementia** | /dÉªËˆmenÊƒÉ™/ | n. | ç—´å‘†ç—‡ | è®¤çŸ¥åŠŸèƒ½é€€åŒ–çš„ç–¾ç—… | "Alzheimer's is the leading cause of dementia." | â˜…â˜…â˜…â˜…â˜† |
| 7 | **Regulatory T cells** | /ËˆreÉ¡jÉ™lÉ™tÉ”Ëri tiË selz/ | n. | è°ƒèŠ‚æ€§Tç»†èƒ | æŠ‘åˆ¶å…ç–«ååº”çš„ç»†èƒ | "Regulatory T cells act as peacekeepers in the immune system." | â˜…â˜…â˜…â˜†â˜† |
| 8 | **Contraceptive** | /ËŒkÉ’ntrÉ™ËˆseptÉªv/ | n./adj. | é¿å­•è¯/é¿å­•çš„ | é˜²æ­¢æ€€å­•çš„æªæ–½ | "A new male contraceptive passed safety trials." | â˜…â˜…â˜…â˜†â˜† |
| 9 | **Avian influenza** | /ËˆeÉªviÉ™n ËŒÉªnfluËˆenzÉ™/ | n. | ç¦½æµæ„Ÿ | é¸Ÿç±»æ„ŸæŸ“çš„æµæ„Ÿç—…æ¯’ | "Avian influenza spread through dairy cattle in 2025." | â˜…â˜…â˜…â˜†â˜† |
| 10 | **Reversible** | /rÉªËˆvÉœËsÉ™bl/ | adj. | å¯é€†çš„ | å¯ä»¥æ¢å¤æ­£å¸¸çŠ¶æ€çš„ | "The contraceptive's effects are reversible." | â˜…â˜…â˜…â˜…â˜† |
| 11 | **One Health** | /wÊŒn hÉ›lÎ¸/ | n. | åŒä¸€å¥åº· | äººã€åŠ¨ç‰©ã€ç¯å¢ƒå¥åº·çš„æ•´ä½“æ–¹æ³• | "One Health approach connects human and animal health." | â˜…â˜…â˜…â˜†â˜† |
| 12 | **Gut-brain axis** | /É¡ÊŒt breÉªn ËˆÃ¦ksÉªs/ | n. | è‚ è„‘è½´ | è‚ é“ä¸å¤§è„‘çš„é€šä¿¡ç³»ç»Ÿ | "GLP-1 drugs affect the gut-brain axis." | â˜…â˜…â˜…â˜†â˜† |
| 13 | **Butyrate** | /ËˆbjuËtÉªreÉªt/ | n. | ä¸é…¸ç› | æœ‰ç›Šçš„è‚ é“ä»£è°¢ç‰© | "Butyrate aids digestion and nutrient absorption." | â˜…â˜…â˜†â˜†â˜† |
| 14 | **Alcohol consumption** | /ËˆÃ¦lkÉ™hÉ’l kÉ™nËˆsÊŒmpÊƒn/ | n. | é¥®é…’é‡ | é…’ç²¾çš„æ‘„å…¥ | "GLP-1 drugs may reduce alcohol consumption." | â˜…â˜…â˜…â˜…â˜† |
| 15 | **Food preferences** | /fuËd ËˆprefrÉ™nsÉªz/ | n. | é£Ÿç‰©åå¥½ | å¯¹æŸäº›é£Ÿç‰©çš„å€¾å‘æ€§ | "The drug changed patients' food preferences." | â˜…â˜…â˜…â˜†â˜† |

### å­¦æœ¯å’Œä¸“ä¸šè¡¨è¾¾

| è¡¨è¾¾ | å«ä¹‰ | è¯­å¢ƒ/ç”¨æ³• | ä¾‹å¥ |
|------|------|----------|------|
| **Provide evidence for** | æä¾›è¯æ®æ”¯æŒ | å­¦æœ¯è®¨è®º | "The study provides evidence for the virus-dementia link." |
| **Lower the risk of** | é™ä½...é£é™© | æµè¡Œç—…å­¦ | "Vaccination lowers the risk of dementia." |
| **Pass clinical trials** | é€šè¿‡ä¸´åºŠè¯•éªŒ | è¯ç‰©ç ”å‘ | "The drug passed Phase I safety trials." |
| **Jump between species** | è·¨ç‰©ç§ä¼ æ’­ | äººç•œå…±æ‚£ç—… | "The virus can jump between species." |
| **Raise questions about** | å¼•å‘å¯¹...çš„è´¨ç–‘ | ç ”ç©¶è®¨è®º | "The data raises questions about long-term safety." |
| **Be associated with** | ä¸...ç›¸å…³è” | ç»Ÿè®¡å­¦è¡¨è¾¾ | "Coffee is associated with gut health." |

### æ­é… (Collocations)

| æ­é… | å«ä¹‰ | ä¾‹å¥ |
|------|------|------|
| **Develop dementia** | æ‚£ç—´å‘†ç—‡ | "People who received the vaccine were less likely to develop dementia." |
| **Immune system** | å…ç–«ç³»ç»Ÿ | "Regulatory T cells protect the immune system from attacking itself." |
| **Spread through** | ä¼ æ’­é€šè¿‡ | "The virus spread through dairy cattle populations." |
| **Maintain tolerance** | ç»´æŒè€å— | "These cells maintain immune tolerance." |
| **Reduce consumption** | å‡å°‘æ‘„å…¥ | "Drugs may reduce alcohol consumption." |

### è¯æ— (Word Families)

| åŸºç¡€è¯ | è¯æ€§ | è¯æ—æˆå‘˜ | ä¾‹å¥ |
|--------|------|----------|------|
| **Tolerate** | v. | tolerate, tolerance, tolerant, toleration | "The immune system must tolerate self-tissues." |
| **Regulate** | v. | regulate, regulation, regulatory, regulator | "Regulatory T cells control immune responses." |
| **Consume** | v. | consume, consumption, consumer | "Alcohol consumption decreased in the study group." |
| **Prefer** | v. | prefer, preference, preferential | "Patients showed changed food preferences." |

---

## âœï¸ è¯­æ³•ä¸å¥å‹

### å…³é”®å¥å‹

1. **A provides the strongest evidence yet that...**
   - **ç»“æ„**: ä¸»è¯­ + æä¾› + æœ€å¼ºè¯æ® + thatä»å¥
   - **ç”¨æ³•**: ç”¨äºå¼ºè°ƒæŸé¡¹ç ”ç©¶çš„çªç ´æ€§å‘ç°
   - **ä¾‹å¥**: "The Welsh study provides the strongest evidence yet that vaccines can protect against dementia."
   - **ä½ çš„ç»ƒä¹ **: _____________________________________

2. **...raise questions about...**
   - **ç»“æ„**: ä¸»è¯­ + å¼•å‘é—®é¢˜ + aboutåè¯
   - **ç”¨æ³•**: è¡¨ç¤ºæŸå‘ç°å¼•å‘äº†å¯¹æŸäº‹çš„è´¨ç–‘æˆ–æ‹…å¿§
   - **ä¾‹å¥**: "New data raises questions about long-term GLP-1 drug use."
   - **ä½ çš„ç»ƒä¹ **: _____________________________________

3. **...be associated with...**
   - **ç»“æ„**: ä¸»è¯­ + ä¸...ç›¸å…³è”
   - **ç”¨æ³•**: è¡¨ç¤ºç»Ÿè®¡å­¦ä¸Šçš„å…³è”æ€§ï¼ˆéå› æœå…³ç³»ï¼‰
   - **ä¾‹å¥**: "Regular coffee consumption is associated with gut health benefits."
   - **ä½ çš„ç»ƒä¹ **: _____________________________________

4. **Scientists are exploring how to use X for Y**
   - **ç»“æ„**: ç§‘å­¦å®¶ä»¬æ­£åœ¨æ¢ç´¢å¦‚ä½•ç”¨Xæ¥æ²»ç–—Y
   - **ç”¨æ³•**: æè¿°ç ”ç©¶åº”ç”¨æ–¹å‘
   - **ä¾‹å¥**: "Scientists are exploring how to use regulatory T cells for treating autoimmune diseases."
   - **ä½ çš„ç»ƒä¹ **: _____________________________________

### è¿‡æ¸¡è¯ä¸çŸ­è¯­

| ç±»åˆ« | è¯æ±‡/çŸ­è¯­ | ç”¨æ³• | ä¾‹å¥ |
|------|----------|------|------|
| æ·»åŠ ä¿¡æ¯ | **Furthermore**, | æ·»åŠ ç±»ä¼¼è§‚ç‚¹ | "The vaccine reduces dementia risk. Furthermore, it may protect against other conditions." |
| æ·»åŠ ä¿¡æ¯ | **In addition**, | æ·»åŠ æ”¯æŒç‚¹ | "We studied dementia. In addition, we examined Parkinson's disease." |
| å¯¹æ¯” | **However**, | æ˜¾ç¤ºå·®å¼‚ | "The drug is effective. However, many patients stop taking it." |
| å¯¹æ¯” | **On the other hand**, | æå‡ºæ›¿ä»£è§‚ç‚¹ | "Coffee has benefits. On the other hand, excessive consumption has risks." |
| å› æœ | **Consequently**, | æ˜¾ç¤ºç»“æœ | "Many stopped treatment. Consequently, weight regain occurred." |
| å› æœ | **Therefore**, | å¾—å‡ºç»“è®º | "The virus spreads between species. Therefore, we need One Health approaches." |
| ä¸¾ä¾‹ | **For instance**, | å¼•å…¥ä¾‹å­ | "Many diseases have viral components. For instance, some cancers are virus-related." |
| ä¸¾ä¾‹ | **Such as**, | åˆ—ä¸¾ä¾‹å­ | "Regulatory T cells may treat autoimmune diseases such as diabetes and arthritis." |

### å¸¸è§é”™è¯¯è­¦ç¤º âš ï¸

âš ï¸ **"correlate with" vs "correlate to"**
- **é”™è¯¯**: The vaccine correlates to lower dementia risk.
- **æ­£ç¡®**: The vaccine correlates with lower dementia risk.
- **è§£é‡Š**: "Correlate" always takes "with", never "to".

âš ï¸ **"affect" vs "effect"**
- **é”™è¯¯**: The drug had a positive effect on the immune system (as verb).
- **æ­£ç¡®**: The drug positively affects the immune system.
- **è§£é‡Š**: "Affect" is usually a verb (to influence). "Effect" is usually a noun (the result).

---

## ğŸ“ ç†è§£æ£€æŸ¥

### å¿«é€Ÿå›é¡¾é—®é¢˜

1. **What percentage reduction in dementia risk did the shingles vaccine provide?**
   - **ç­”æ¡ˆ**: 20 percent reduction over seven years.

2. **What are regulatory T cells sometimes called?**
   - **ç­”æ¡ˆ**: "Peacekeepers" (because they prevent immune overreaction).

3. **What percentage of people stop GLP-1 drugs within two years?**
   - **ç­”æ¡ˆ**: The vast majority (specific percentage not stated in the source).

4. **What approach connects human, animal, and environmental health?**
   - **ç­”æ¡ˆ**: One Health approach.

5. **What beneficial compound does Lawsonibacter asaccharolyticus produce?**
   - **ç­”æ¡ˆ**: Butyrate.

### è®¨è®ºè¯é¢˜

1. **ç–«è‹—ä¸ç¥ç»é€€è¡Œæ€§ç–¾ç—…**
   - "Do you think viral infections might contribute to neurodegenerative diseases? Why or why not?"
   - *æŒ‡å¯¼*: Consider evidence from the shingles vaccine study.

2. **GLP-1è¯ç‰©çš„é•¿æœŸä½¿ç”¨**
   - "What are the implications of most people stopping GLP-1 treatment within two years?"
   - *æŒ‡å¯¼*: Think about drug adherence, cost, and side effects.

3. **One Healthç†å¿µçš„åº”ç”¨**
   - "How might the One Health approach help prevent future pandemics?"
   - *æŒ‡å¯¼*: Consider connections between human and animal health.

### åæ€æç¤º

1. **è‡ªæˆ‘åæ€**: Which epidemiology terms from this episode were new to you? How will you remember them?
   - æˆ‘çš„å›ç­”: _____________________________________

2. **åº”ç”¨**: How could you use the phrase "provide evidence for" in your own research discussions?
   - æˆ‘çš„åº”ç”¨: _____________________________________

---

## ğŸ”„ ç›¸å…³æ¦‚å¿µ

### ä¸ä¹‹å‰å‰§é›†çš„è¿æ¥

- æš‚æ— ï¼ˆç¬¬ä¸€æœŸï¼‰

### è¿›ä¸€æ­¥æ¢ç´¢

- **mRNAç–«è‹—æŠ€æœ¯**: Learn about the technology behind modern vaccines
- **è‚ é“å¾®ç”Ÿç‰©ç»„ç ”ç©¶**: Explore the gut microbiome and health
- **æµè¡Œç—…å­¦æ–¹æ³•**: Study causal inference methods like Mendelian randomization

---

## ğŸ“š é¢å¤–èµ„æº

### æ¨èé˜…è¯»

- Scientific American: 2025å¹´å¥åº·å‘ç°ç³»åˆ—æ–‡ç« 
- Nature Reviews Immunology: è°ƒèŠ‚æ€§Tç»†èƒç ”ç©¶ç»¼è¿°
- WHO: One Healthå®˜æ–¹æŒ‡å—

### åœ¨çº¿èµ„æº

- [Scientific American Healthé¢‘é“](https://www.scientificamerican.com/)
- [Johns Hopkins Public Health](https://publichealth.jhu.edu/)
- [WHO - One Health](https://www.who.int/health-topics/one-health)

### ç»ƒä¹ ç»ƒä¹ 

- **è¯æ±‡ç»ƒä¹ **: ç”¨ä»Šå¤©å­¦åˆ°çš„5ä¸ªæ–°è¯å†™3ä¸ªå¥å­
- **å£è¯­ç»ƒä¹ **: å‘æœ‹å‹è§£é‡Šå¸¦çŠ¶ç–±ç–¹ç–«è‹—ä¸ç—´å‘†ç—‡çš„å…³ç³»
- **å†™ä½œç»ƒä¹ **: å†™ä¸€æ®µå…³äºGLP-1è¯ç‰©çš„100å­—æ‘˜è¦

---

## ğŸ“Š å­¦ä¹ è¿›åº¦

### è‡ªæˆ‘è¯„ä¼°

| æŠ€èƒ½ | å­¦ä¹ å‰ | å­¦ä¹ å(1å‘¨) | å­¦ä¹ å(1æœˆ) |
|------|--------|-------------|-------------|
| è¯æ±‡é‡ | â­â­â˜†â˜†â˜† | â­â­â­â˜†â˜† | â­â­â­â­â˜† |
| ç†è§£èƒ½åŠ› | â­â­â˜†â˜†â˜† | â­â­â­â˜†â˜† | â­â­â­â­â˜† |
| å£è¯­è¡¨è¾¾ | â­â­â˜†â˜†â˜† | â­â­â­â˜†â˜† | â­â­â­â­â˜† |
| å†™ä½œèƒ½åŠ› | â­â­â˜†â˜†â˜† | â­â­â­â˜†â˜† | â­â­â­â­â˜† |

### ç¬”è®°ä¸è§‚å¯Ÿ

**æˆ‘çš„ç¬”è®°**:
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________

**ä¸‹ä¸€å‰§é›†çš„é—®é¢˜**:
_______________________________________________________________________________
_______________________________________________________________________________

---

## ğŸ¯ è¡ŒåŠ¨é¡¹ç›®

- [ ] å¤ä¹ è¯æ±‡è¡¨ï¼ˆå­¦ä¹ æ—¥ï¼‰
- [ ] ç»ƒä¹ å¥å‹é€ å¥ï¼ˆå­¦ä¹ æ—¥2-3ï¼‰
- [ ] å®Œæˆç†è§£é—®é¢˜ï¼ˆå­¦ä¹ æ—¥3ï¼‰
- [ ] ç”¨æ–°è¡¨è¾¾å†™ä½œï¼ˆå­¦ä¹ æ—¥4-5ï¼‰
- [ ] ä¸å­¦ä¹ ä¼™ä¼´è®¨è®ºï¼ˆå­¦ä¹ æ—¥6-7ï¼‰

---

## ğŸ“… å­¦ä¹ è®¡åˆ’

| å¤©æ•° | æ´»åŠ¨ | æ—¶é—´ | å®Œæˆ |
|------|------|------|------|
| ç¬¬1å¤© | å¬æ’­å®¢+è®°ç¬”è®° | 20åˆ†é’Ÿ | [ ] |
| ç¬¬2å¤© | å¤ä¹ è¯æ±‡ | 15åˆ†é’Ÿ | [ ] |
| ç¬¬3å¤© | è¯­æ³•ç»ƒä¹  | 20åˆ†é’Ÿ | [ ] |
| ç¬¬4å¤© | å£è¯­ç»ƒä¹  | 15åˆ†é’Ÿ | [ ] |
| ç¬¬5å¤© | å†™ä½œç»ƒä¹  | 20åˆ†é’Ÿ | [ ] |
| ç¬¬6å¤© | è®¨è®º | 30åˆ†é’Ÿ | [ ] |
| ç¬¬7å¤© | è‡ªæˆ‘è¯„ä¼° | 15åˆ†é’Ÿ | [ ] |

---

*å­¦ä¹ ç¬”è®°ç”Ÿæˆæ—¶é—´: 2026-02-11*
*ä½¿ç”¨English Learning Podcast Generator Skill*
*ä¸‹ä¸€æ¬¡å¤ä¹ æ—¥æœŸ: 2026-02-18*
